Title: Aarkstore - Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014
1Vaginal Atrophy (Atrophic Vaginitis) - Pipeline
Review, H2 2014
Pharmaceutical and Healthcare Market Research
Report
2Summary
- Vaginal Atrophy (Atrophic Vaginitis) - Pipeline
Review, H2 2014, provides an overview of the
Vaginal Atrophy (Atrophic Vaginitis)s therapeutic
pipeline. - This report provides comprehensive information
on the therapeutic development for Vaginal
Atrophy (Atrophic Vaginitis), complete with
comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type, along with latest updates, and
featured news and press releases. It also reviews
key players involved in the therapeutic
development for Vaginal Atrophy (Atrophic
Vaginitis) and special features on late-stage and
discontinued projects. - Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
3Scope
- - The report provides a snapshot of the global
therapeutic landscape of Vaginal Atrophy
(Atrophic Vaginitis)- The report reviews key
pipeline products under drug profile section
which includes, product description, MoA and RD
brief, licensing and collaboration details
other developmental activities - The report
reviews key players involved in the therapeutics
development for Vaginal Atrophy (Atrophic
Vaginitis) and enlists all their major and minor
projects- The report summarizes all the dormant
and discontinued pipeline projects - A review of
the Vaginal Atrophy (Atrophic Vaginitis) products
under development by companies and
universities/research institutes based on
information derived from company and
industry-specific sources- Pipeline products
coverage based on various stages of development
ranging from pre-registration till discovery and
undisclosed stages
- Browse full report or Sample Request _at_
- http//www.aarkstore.com/pharmaceuticals-healthcar
e/100597/vaginal-atrophy-atrophic-vaginitis-pipeli
ne-review-h2-2014
4Reasons to buy
- - Provides strategically significant competitor
information, analysis, and insights to formulate
effective RD development strategies- Identify
emerging players with potentially strong product
portfolio and create effective counter-strategies
to gain competitive advantage- Develop strategic
initiatives by understanding the focus areas of
leading companies- Identify and understand
important and diverse types of therapeutics under
development for Vaginal Atrophy (Atrophic
Vaginitis)- Plan mergers and acquisitions
effectively by identifying key players of the
most promising pipeline- Devise corrective
measures for pipeline projects by understanding
Vaginal Atrophy (Atrophic Vaginitis) pipeline
depth and focus of Indication therapeutics-
Develop and design in-licensing and out-licensing
strategies by identifying prospective partners
with the most attractive projects to enhance and
expand business potential and Scope- Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline
5Table of Content
- IntroductionREPORT COVERAGEVaginal Atrophy
(Atrophic Vaginitis) OverviewTherapeutics
DevelopmentPipeline Products for Vaginal Atrophy
(Atrophic Vaginitis) - OverviewPipeline Products
for Vaginal Atrophy (Atrophic Vaginitis) -
Comparative AnalysisVaginal Atrophy (Atrophic
Vaginitis) - Therapeutics under Development by
CompaniesVaginal Atrophy (Atrophic Vaginitis) -
Pipeline Products GlanceLate Stage
ProductsClinical Stage ProductsEarly Stage
ProductsVaginal Atrophy (Atrophic Vaginitis) -
Products under Development by CompaniesVaginal
Atrophy (Atrophic Vaginitis) - Companies Involved
in Therapeutics DevelopmentFoamix Ltd.Pantarhei
Bioscience BV
6List of Tables
- Number of Products under Development for Vaginal
Atrophy (Atrophic Vaginitis), H2 2014Number of
Products under Development for Vaginal Atrophy
(Atrophic Vaginitis) - Comparative Analysis, H2
2014Number of Products under Development by
Companies, H2 2014Comparative Analysis by Late
Stage Development, H2 2014Comparative Analysis
by Clinical Stage Development, H2
2014Comparative Analysis by Early Stage
Development, H2 2014Products under Development
by Companies, H2 2014Vaginal Atrophy (Atrophic
Vaginitis) - Pipeline by Foamix Ltd., H2
2014Vaginal Atrophy (Atrophic Vaginitis) -
Pipeline by Pantarhei Bioscience BV, H2
2014Vaginal Atrophy (Atrophic Vaginitis) -
Pipeline by Hygeia Therapeutics, Inc., H2
2014Vaginal Atrophy (Atrophic Vaginitis) -
Pipeline by EndoCeutics, Inc., H2 2014Vaginal
Atrophy (Atrophic Vaginitis) - Pipeline by
TherapeuticsMD Inc., H2 2014Vaginal Atrophy
(Atrophic Vaginitis) - Pipeline by Peptonic
medical AB, H2 2014
7List of Figures
- Number of Products under Development for Vaginal
Atrophy (Atrophic Vaginitis), H2 2014Number of
Products under Development for Vaginal Atrophy
(Atrophic Vaginitis) - Comparative Analysis, H2
2014Number of Products under Development by
Companies, H2 2014Assessment by Monotherapy
Products, H2 2014Number of Products by Top 10
Target, H2 2014Number of Products by Stage and
Top 10 Target, H2 2014Number of Products by Top
10 Mechanism of Action, H2 2014Number of
Products by Stage and Top 10 Mechanism of Action,
H2 2014Number of Products by Top 10 Route of
Administration, H2 2014Number of Products by
Stage and Top 10 Route of Administration, H2
2014Number of Products by Top 10 Molecule Type,
H2 2014Number of Products by Stage and Top 10
Molecule Type, H2 2014
8Related Reports
- Sinusitis-Pipeline Insights, 2015
- Oligodendroglioma-Pipeline Insights, 2015
- Familial Hypercholesterolemia (Type II
Hyperlipoproteinemia)-Pipeline Insights, 2015 - Fatty Liver Disease-Pipeline Insights, 2015
- Skin And Skin Structure Infections by
S.Pneumoniae-Pipeline Insights, 2015 - Opioid-Induced Constipation (OIC)-Pipeline
Insights, 2015 - Female Infertility-Pipeline Insights, 2015
- Optic Neuritis-Pipeline Insights, 2015
9Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953